Related Experiment Video
Updated: Apr 20, 2026
05:25
Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies
Published on: December 29, 2021
3.1K
Cannabidiol at the crossroads: panacea, placebo, or problem?
L Cinnamon Bidwell1, Ryan Vandrey2
1Institute of Cognitive Science, Department of Psychology and Neuroscience, University of Colorado Boulder, Boulder, CO, USA. lcb@colorado.edu.
Summary
Cannabidiol (CBD) shows therapeutic potential but faces challenges due to product variability and inconsistent evidence. Improving research quality and regulatory oversight is crucial for its clinical translation and safe use.
Area of Science:
- Pharmacology and Therapeutics
- Cannabinoid Research
- Evidence-Based Medicine
Background:
- Cannabidiol (CBD) is increasingly recognized for its potential therapeutic applications and wellness benefits.
- Evidence supporting CBD's efficacy and safety stems from preclinical, clinical, and real-world observational studies.
- Significant challenges exist in interpreting CBD research due to product diversity (format, dose, formulation) and varying regulatory oversight.
Purpose of the Study:
- To present two contrasting perspectives on Cannabidiol (CBD) research: its therapeutic potential versus concerns regarding evidence quality and product safety.
- To integrate these perspectives to offer guidance for enhancing CBD research consistency and clinical applicability.
- To address the complexities of Cannabidiol (CBD) as a therapeutic agent.
Main Methods:
- Review and synthesis of existing scientific literature on Cannabidiol (CBD).
- Presentation of two expert viewpoints on CBD's therapeutic promise and associated risks.
- Integration of divergent perspectives to formulate recommendations for future research.
Main Results:
- One perspective highlights CBD's pharmacological diversity and potential for treating conditions with limited alternatives.
- The other perspective emphasizes concerns regarding the quality of current evidence, misuse, and risks from unregulated products.
- Discrepancies in product quality, labeling, and regulatory oversight complicate the assessment of CBD's safety and efficacy.
Conclusions:
- Cannabidiol (CBD) presents significant therapeutic potential but requires rigorous, standardized research to overcome current limitations.
- Addressing product variability and enhancing regulatory oversight are essential for reliable clinical translation.
- Future research should focus on reducing variability to improve the understanding and application of CBD therapies.
Related Concept Videos
01:21Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
1.1K
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
1.1K
01:54The Placebo Effect
7.2K
The placebo effect occurs when people's expectations or beliefs influence or determine their experience in a given situation. In other words, simply expecting something to happen can actually make it happen.
7.2K
01:24CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
1.4K
CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its...
1.4K
02:07Blind Procedures
13.9K
Ideally, the people who observe and record the children’s behavior are unaware of who was assigned to the experimental or control group, in order to control for experimenter bias. Experimenter bias refers to the possibility that a researcher’s expectations might skew the results of the study. Remember, conducting an experiment requires a lot of planning, and the people involved in the research project have a vested interest in supporting their hypotheses. If the observers knew which...
13.9K
01:11Blinding
4.2K
Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
4.2K
01:25Analgesia and Pain Management
3.3K
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
3.3K